--- title: "Advanced Biomed | 10-Q: FY2026 Q3 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/286574470.md" datetime: "2026-05-15T13:31:05.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286574470.md) - [en](https://longbridge.com/en/news/286574470.md) - [zh-HK](https://longbridge.com/zh-HK/news/286574470.md) --- # Advanced Biomed | 10-Q: FY2026 Q3 Revenue: USD 0 Revenue: As of FY2026 Q3, the actual value is USD 0. EPS: As of FY2026 Q3, the actual value is USD -0.38. EBIT: As of FY2026 Q3, the actual value is USD -519.72 K. Advanced Biomed Inc. operates as a single reportable segment, thus all financial metrics are presented for the company as a whole. #### Operational Metrics (Continuing Operations) - **Net Income (Loss):** For the three-month period ended March 31, 2026, the net loss was - $488,942, an improvement from a net loss of - $1,383,874 for the same period in 2025. For the nine-month period ended March 31, 2026, the net income was $5,982,078, a significant transition from a net loss of - $2,557,358 for the same period in 2025, primarily driven by a $7,346,684 gain from the disposal of subsidiaries. - **Research and Development Expenses:** These expenses were - $243,226 for the three months ended March 31, 2026, an 11% increase from - $219,966 in the prior year period. For the nine months ended March 31, 2026, they increased by 11% to - $665,140 from - $600,056 in the prior year period, mainly due to increased clinical development activities. - **General and Administrative Expenses:** For the three months ended March 31, 2026, these expenses decreased by 20% to - $276,610 from - $347,541 in the prior year period. However, for the nine months ended March 31, 2026, they increased by 36% to - $646,213 from - $475,093 in the prior year period. - **Other Income (Expense), Net:** This category showed an income of $30,894 for the three months ended March 31, 2026, compared to an expense of - $629,992 in the prior year period. For the nine months ended March 31, 2026, there was an income of $7,565,910, compared to an expense of - $686,957 in the prior year period, largely due to a $7,346,684 gain on disposal of subsidiaries. - **Income (Loss) before Tax Expense:** For the three months ended March 31, 2026, the loss before tax was - $488,942, compared to - $1,197,499 in the prior year period. For the nine months ended March 31, 2026, there was an income of $6,254,557, compared to a loss of - $1,762,106 in the prior year period. #### Discontinued Operations - Loss from discontinued operations, net of tax, was - $272,479 for the nine-month period ended March 31, 2026, an improvement from - $795,252 for the same period in 2025, following the disposal of Advanced Biomed (HK) Limited in December 2025. #### Cash Flow - **Net Cash Used in Operating Activities:** For the nine months ended March 31, 2026, net cash used in operating activities was - $1,363,675, a significant improvement from - $4,281,093 in the prior year period. - **Net Cash Used in Investing Activities:** This amounted to - $15,941 for the nine months ended March 31, 2026, compared to - $11,501 in the prior year period. - **Net Cash Provided by Financing Activities:** This decreased to $1,031,216 for the nine months ended March 31, 2026, from $6,699,767 in the prior year period, primarily due to reduced equity financing. #### Working Capital - As of March 31, 2026, the working capital surplus was $9,100,625, an increase from $3,143,443 as of June 30, 2025. #### Future Outlook and Strategy Advanced Biomed Inc. anticipates continuous losses for the next two to three years, while maintaining its focus on microfluidic biochip technologies for oncology. The company is strategically pivoting towards AI-powered financial audit solutions following an acquisition in April 2026. To support these initiatives, Advanced Biomed Inc. plans to raise additional capital and seeks financial support, despite a current cash balance expected to last at least twelve months, though substantial doubt about its going concern remains. ### Related Stocks - [ADVB.US](https://longbridge.com/en/quote/ADVB.US.md) ## Related News & Research - [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md) - [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md) - [Correction: NextNRG to Host First Quarter 2026 Financial Results Conference Call on May 18, 2026 at 9:00 a.m. ET | NXXT Stock News](https://longbridge.com/en/news/286673001.md) - [Hafnia’s Q1 2026 Financial Results Presentation to Be Held on 27 May 2026 | HAFN Stock News](https://longbridge.com/en/news/287014236.md) - [Keysight Technologies Reports Second Quarter 2026 Results | KEYS Stock News](https://longbridge.com/en/news/286959830.md)